LightPath Q2 FY2024: $7.3M revenue, $1.7M net loss; backlog $21.2M; Lockheed Martin $4.7M order

LIGHTPATH TECHNOLOGIES INC

2024-Q2 EPS reported -$0.08 revenue$15,392,885

Revenue $7.3M; net loss $1.7M; EBITDA loss $0.5M for Q2 ended Dec 31, 2023.
Total backlog $21.2M; received initial $4.7M order from Lockheed Martin partnership for Army infrared camera program.
Secured renewal order of $3.4M for advanced infrared optics, a 36% increase from initial order.
Completed $5M expansion of Orlando facility, increasing footprint from 34,000 to 55,000 sq ft.
CEO: production decision for Lockheed Martin program moved to 2026; ASP $5K-$10K per system; potential tens of thousands of units.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LIGHTPATH TECHNOLOGIES INC reported fiscal 2024 second quarter ended December 31, 2023 results: revenue Revenue of $7.3 million, net income Net loss for the second quarter of fiscal 2024 was $1.7 million.

Period: fiscal 2024 second quarter ended December 31, 2023
Revenue: Revenue of $7.3 million
Net income: Net loss for the second quarter of fiscal 2024 was $1.7 million
Result: reported results

Exact text from the filing

and medical industries, today announced financial results for its fiscal 2024 second quarter ended December 31, 2023. Fiscal 2024 Second Quarter Highlights: · Revenue of $7.3 million for the second quarter of fiscal 2024 · Total backlog at December 31, 2023 of $21.2 million · Net loss for the second quarter of fiscal 2024 was $1.7 million · EBITDA* loss for

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

LIGHTPATH TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001654954-24-001496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.